Phathom Pharmaceuticals (PHAT) Return on Sales (2022 - 2025)
Historic Return on Sales for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to 0.61%.
- Phathom Pharmaceuticals' Return on Sales rose 46300.0% to 0.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.86%, marking a year-over-year increase of 110500.0%. This contributed to the annual value of 6.05% for FY2024, which is 2892600.0% up from last year.
- Latest data reveals that Phathom Pharmaceuticals reported Return on Sales of 0.61% as of Q3 2025, which was up 46300.0% from 1.92% recorded in Q2 2025.
- Phathom Pharmaceuticals' Return on Sales' 5-year high stood at 18.41% during Q3 2023, with a 5-year trough of 116.65% in Q4 2023.
- Its 4-year average for Return on Sales is 7.66%, with a median of 0.61% in 2025.
- In the last 5 years, Phathom Pharmaceuticals' Return on Sales tumbled by -1223700bps in 2023 and then soared by 1141400bps in 2024.
- Phathom Pharmaceuticals' Return on Sales (Quarter) stood at 5.72% in 2022, then crashed by -2138bps to 116.65% in 2023, then soared by 98bps to 2.51% in 2024, then skyrocketed by 76bps to 0.61% in 2025.
- Its Return on Sales stands at 0.61% for Q3 2025, versus 1.92% for Q2 2025 and 3.31% for Q1 2025.